Research status of tyrosine kinase inhibitors discontinuation in patients with chronic myelogenous leukemia
10.3760/cma.j.cn115355-20190324-00102
- VernacularTitle:慢性粒细胞白血病患者停用酪氨酸激酶抑制剂的研究现状
- Author:
Jing WEN
1
;
Weihua ZHANG
Author Information
1. 山西医科大学第一医院血液内科，太原 030001
- From:
Cancer Research and Clinic
2020;32(5):377-380
- CountryChina
- Language:Chinese
-
Abstract:
The clinical applications of tyrosine kinase inhibitors (TKI) greatly prolong the survival of patients with chronic myelogenous leukemia (CML). However, many problems such as drug side effects, drug resistance or intolerance and economic stress caused by long-term drug treatment have prevented a considerable number of patients from adhering to treatment. At present, a number of clinical trials have suggested that CML patients with stable deep molecular response can achieve treatment-free remission. This article reviews the current research status of discontinuation of TKI in patients with CML.
